Allergic Rhinitis Articles & Analysis
24 news found
Fortunately for many of us, and unfortunately for many others, it means flowers will be in bloom after spring rains and some of us will be suffering with seasonal allergic rhinitis, more commonly referred to as hay fever. It’s all about the coughing, the red eyes, and the sneezing from that point on. For those that are allergic to pollen ...
This article describes a new method to reduce nasal obstruction in patients with chronic rhinitis when conventional medical therapy has failed. Rhinitis is chronic (CR) when symptoms of nasal obstruction, sneezing, itchy nose, and rhinorrhea persist for more than 3 months each year. ...
The company's portfolio includes six clinical-stage programs: a Phase 2b study to treat patients with acne vulgaris or acne, a Phase 2 trial in hypertension, a Phase 2 study to treat patients with eczema (atopic dermatitis), a Phase 2 study to treat migraines, a Phase 2 study to treat rosacea, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as ...
This Christmas season, when families gather together and consume tasty holiday foods, it is essential to be aware of allergic reactions, which usually increase during this period. Food allergies are estimated to affect 1% to 10% of adults and children in developed countries[1]. ...
More than 90% of children in the trial had at least one concurrent atopic medical condition such as allergic rhinitis and atopic dermatitis. The primary endpoint was the annualized rate of severe asthma exacerbations over one year, and the key secondary endpoint was the change from baseline in percentage of predicted pre-bronchodilator FEV1 (FEV1pp) at week 12. ...
Hay fever, also known as allergic rhinitis, occurs when allergens like pollen enter the body and the immune system mistakenly identifies them as a threat. For those with allergic rhinitis, the body then responds to the allergen by releasing chemicals that can cause symptoms. Pollen exposure can also trigger symptoms of ...
Together, this is designed to reduce the risk of upper respiratory tract viral infections and promote alleviation of allergic symptoms. In human nasal epithelium cells infected by SARS-CoV-2, Bentrio™ was shown to reduce the infectious viral load by more than 99% when used for prevention. ...
Together, this is designed to reduce the risk of upper respiratory tract viral infections and promote alleviation of allergic symptoms. In human nasal epithelium cells infected by SARS-CoV-2, Bentrio™ was shown to reduce the infectious viral load by more than 99% when used for prevention. ...
” One of the major goals of the World Sinus Health Awareness Day inaugural education campaign is to delineate common ailments of the nose and sinus such as allergic and non-allergic rhinitis and acute and chronic rhinosinusitis (CRS) from COVID-19-related symptoms by comparing and differentiating the symptoms of each based on data-driven ...
The company's portfolio includes multiple clinical-stage programs: a completed Phase 2 study to treat patients with acne vulgaris or acne, a Phase 1b study to treat patients with pediatric eczema (atopic dermatitis), a Phase 2 study to treat patients with adult eczema (atopic dermatitis), a Phase 2 study for the prevention of episodic migraines, and a Phase 1b/2a clinical trial for the treatment ...
The company's portfolio includes multiple clinical-stage programs: a completed Phase 2 study to treat patients with acne vulgaris or acne, a Phase 1b study to treat patients with pediatric eczema (atopic dermatitis), a Phase 2 study to treat patients with adult eczema (atopic dermatitis), a Phase 2 study for the prevention of episodic migraines, and a Phase 1b/2a clinical trial for the treatment ...
About Oral Mucosal Immunotherapy (OMIT) Respiratory allergies affect at least 60 million people in the United States, resulting in 11.1 million visits to the doctor in 2010. 100 million Europeans suffer from allergic rhinitis and 70 million suffer from asthma. Symptomatic treatment, at a global cost of over $25 billion yearly, keeps symptoms at bay temporarily ...
Evolve BioSystems, Inc., a global leader dedicated to improving human health through the gut microbiome, today announced a collaboration with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to conduct a clinical study in children at risk for developing atopic dermatitis. The study will assess the effects of introducing a specific gut ...
We will now seek out strategic partners who share our goal of improving the lives of patients who have allergic disease. While immunotherapy has long been recognized as the only allergy therapy that targets the underlying immune condition, subcutaneous and sublingual immunotherapy have limitations for many patients. The sad result is that far too many allergic ...
Additionally, many children who suffer from atopic dermatitis in their youth also go on to disproportionally suffer from certain diseases later in life, including 43% of children with severe atopic dermatitis before the age of 8 developing asthma and 45% developing allergic rhinitis according to one recent study.2 “Our goal is to alleviate both the ...
” AOBiome has six ongoing clinical programs in acne, eczema, rosacea, allergic rhinitis, migraine, and hypertension, along with multiple ongoing preclinical programs, including ones addressing pulmonary and gastrointestinal disorders. ...
"Neurent Medical has based its rhinitis device on its extensive research on neuronal activity in the nasal cavity and the cellular makeup of the nasal mucosa. These guiding principles have enabled the product to stand out as a low-powered RF treatment that targets the autonomic supply to the nasal turbinates, positively impacting both allergic and ...
“We acknowledge that the regulations set by the German authorities, are important for allergic patients in Germany, the largest European allergy market. Therefore, we were determined to register our sublingual birch and trees products. ...
The company's portfolio includes six clinical-stage programs in the following indications; acne vulgaris, hypertension, eczema (atopic dermatitis), migraine, rosacea, and allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory ...
The company's portfolio includes six clinical-stage programs: A Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, a Phase 2 study to treat patients with atopic dermatitis, a Phase 2 study to treat episodic migraines, a Phase 2 study to study rosacea, and a Phase 1b/2a clinical trial in allergic rhinitis, as ...